Rapport Therapeutics, Inc. Common StockRAPPNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P82
Within normal range
vs 2Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 35.81% |
| Q3 2025 | -1.77% |
| Q2 2025 | 15.88% |
| Q1 2025 | 13.80% |
| Q4 2024 | 10.65% |
| Q3 2024 | -0.93% |
| Q2 2024 | 25.47% |
| Q1 2024 | 5.98% |
| Q4 2023 | 55.66% |
| Q3 2023 | 60.56% |
| Q2 2023 | 21.08% |
| Q1 2023 | 0.00% |